Primex Pharmaceuticals at Euroanaesthesia 2017: Next Innovation in the Management of Paediatric Sedation
With a growing number of surgical and diagnostic procedures being performed globally, children are subjected to increased levels of anxiety that may occur before anaesthesia or thereafter, leading to behavioural stress and frightened, phobic and non-cooperative children with traumas.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170605005326/en/
Premedication may be administered to reduce the preoperative anxiety. However, one of the challenges facing paediatric anaesthesiologists is the lack of suitable medications, either due to their lack of acceptability, or their being unregistered and therefore used outside of their medical indication.
An innovative oral solution for children, ADV6209, has been developed to improve the management of paediatric sedation.
Dr. Michael Brackhahn from the Department of Anaesthesiology at the Children’s Hospital ‘Auf der Bult’ in Hannover, Germany, presented results from the clinical and PK studies along with his own experience of ADV6209 in procedural sedation. The results show the rapid sedative effect by paediatric patients in clinical practice as one of the main advantages of this formulation.
"ADV6209 is an oral solution and is currently under regulatory submission in the EU. We are excited to bring the next anaesthetic innovation to the market”, said Mr. Alan Knox , Head of Global Marketing at Primex Pharmaceuticals. "Anaesthesiologists have been asking for a licensed paediatric sedative that is well accepted by children, and would thereby evolve the management of procedural sedation, such as in emergency and diagnostic procedures."
Mr. Kari Sarvanto, CEO and Co-Founder of Primex, added: “Primex is proud to bring a patient-friendly oral solution to a market with such an unmet need. We are committed to making Primex Pharmaceuticals the leading global anaesthesia pharmaceutical company, and we aim to expand further into paediatrics and into orphan pharmaceuticals.”
About Primex Pharmaceuticals:
Primex Pharmaceuticals is a leading innovative anaesthesia company. A strong trusted anaesthesia portfolio is helping patients undergo a wide range of medical procedures. Primex Pharmaceuticals will continue to identify, acquire and bring to the market new medications that complete the ‘Triad of Anaesthesia’.
Primex Pharmaceuticals' global partner network operates in over 40 countries. The company is headquartered in Switzerland; all Primex products are manufactured in Europe.
Mr. Kari Sarvanto, CEO
Mobile: +41 796 162 694
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
SEOUL-SEMICONDUCTOR23.3.2018 19:30 | pressemeddelelse
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine
ELLIOTT-MANAGEMENT-CORP23.3.2018 17:07 | pressemeddelelse
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance
CO-CLOVIS-ONCOLOGY-INC23.3.2018 13:54 | pressemeddelelse
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe
CO-CLOVIS-ONCOLOGY-INC23.3.2018 13:52 | pressemeddelelse
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets
JANSSEN23.3.2018 13:48 | pressemeddelelse
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)
AITHEON23.3.2018 13:02 | pressemeddelelse
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum